Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.

@article{Straus2006QualityoflifeAH,
  title={Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.},
  author={David M. Straus and Marcia A. Testa and Brenda J Sarokhan and Myron S. Czuczman and Anil Tulpule and Ralph R Turner and Shirley A. Riggs},
  journal={Cancer},
  year={2006},
  volume={107 8},
  pages={1909-17}
}
BACKGROUND Chemotherapy-related anemia is prevalent among patients with hematologic malignancies. A randomized, open-label, multicenter trial of early versus late epoetin alfa in this population was conducted, focusing on quality of life (QOL). METHODS Patients with non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia, or multiple myeloma and baseline hemoglobin of 10 to 12 g/dL who were scheduled for > or = 4 months of myelosuppressive chemotherapy were randomized to receive… CONTINUE READING
18 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Cognitive effects of once weekly (QW) epoetin alfa in anemic patients (pts) with hematologic malignancies receiving chemotherapy (CT): interim results of the EPOLYM trial

  • C Gisselbrecht, H Tesch, E Jourdan
  • Abstract
  • 2004
1 Excerpt

Biases in responding. Health Measurement Scales: A Practical Guide to Their Development and Use

  • DL Streiner, GR Norman
  • Early Epoetin alfa in Hematologic Malignancy…
  • 2003

Similar Papers

Loading similar papers…